{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:17:05Z","timestamp":1787314625818,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Capital Funds for Health Improvement and Research","award":["2024-2-5012"],"award-info":[{"award-number":["2024-2-5012"]}]},{"name":"The Special research project on monitoring and evaluation of the use of key clinical drugs by the Committee for Drug evaluation of Chinese Research Hospital Association","award":["Y2023FH-YWPJ03-101"],"award-info":[{"award-number":["Y2023FH-YWPJ03-101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11096-025-01867-6","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T10:07:16Z","timestamp":1738318036000},"page":"755-766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"47","author":[{"given":"Xiao","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-2800","authenticated-orcid":false,"given":"Man","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"4","key":"1867_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/jth.14727","volume":"18","author":"T Lissitchkov","year":"2020","unstructured":"Lissitchkov T, Madan B, Djambas Khayat C, et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost. 2020;18(4):815\u201324. https:\/\/doi.org\/10.1111\/jth.14727.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"1867_CR2","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1016\/j.jtha.2023.08.014","volume":"21","author":"AS Wolberg","year":"2023","unstructured":"Wolberg AS. Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost. 2023;21(11):3005\u201315. https:\/\/doi.org\/10.1016\/j.jtha.2023.08.014.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"1867_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/j.1538-7836.2006.02014.x","volume":"4","author":"F Peyvandi","year":"2006","unstructured":"Peyvandi F, Haertel S, Knaub S, et al. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006;4(7):1634\u20137. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02014.x.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1867_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2450\/2011.0015-11","volume":"10","author":"M Franchini","year":"2012","unstructured":"Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10(1):23\u20137. https:\/\/doi.org\/10.2450\/2011.0015-11.","journal-title":"Blood Transfus"},{"key":"1867_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.943674","volume":"13","author":"B Leng","year":"2022","unstructured":"Leng B, Shen C, Gao T, et al. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: a multicenter retrospective study in China. Front Pharmacol. 2022;13:943674. https:\/\/doi.org\/10.3389\/fphar.2022.943674.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1867_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107062","volume":"63","author":"J Guo","year":"2024","unstructured":"Guo J, Wang S, Zhou M, et al. Nomogram for the prediction of tigecycline-induced hypofibrinogenaemia in a Chinese population. Int J Antimicrob Agents. 2024;63(2):107062. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107062.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1867_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264351","volume":"17","author":"DS Post","year":"2022","unstructured":"Post DS, van der Veer A, Schijns O, et al. Assessment of need for hemostatic evaluation in patients taking valproic acid: a retrospective cross-sectional study. PLoS ONE. 2022;17(2):e0264351. https:\/\/doi.org\/10.1371\/journal.pone.0264351.","journal-title":"PLoS ONE"},{"issue":"1","key":"1867_CR8","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41598-023-36246-6","volume":"13","author":"T He","year":"2023","unstructured":"He T, Ling J, Yang J. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis. Sci Rep. 2023;13(1):9050. https:\/\/doi.org\/10.1038\/s41598-023-36246-6.","journal-title":"Sci Rep"},{"issue":"Suppl 2","key":"1867_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12911-022-01869-8","volume":"22","author":"Y Pan","year":"2022","unstructured":"Pan Y, Xu R. Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records. BMC Med Inform Decis Mak. 2022;22(Suppl 2):155. https:\/\/doi.org\/10.1186\/s12911-022-01869-8.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"6","key":"1867_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577\u201387. https:\/\/doi.org\/10.1007\/s40264-015-0289-5.","journal-title":"Drug Saf"},{"key":"1867_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cca.2019.09.006","volume":"499","author":"J Zierk","year":"2019","unstructured":"Zierk J, Ganslandt T, Rauh M, et al. Data mining of reference intervals for coagulation screening tests in adult patients. Clin Chim Acta. 2019;499:108\u201314. https:\/\/doi.org\/10.1016\/j.cca.2019.09.006.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1867_CR12","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/ATVBAHA.117.308564","volume":"37","author":"S Kattula","year":"2017","unstructured":"Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2017;37(3):e13\u201321. https:\/\/doi.org\/10.1161\/ATVBAHA.117.308564.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1867_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","volume":"76","author":"J Hu","year":"2020","unstructured":"Hu J, Xiao YH, Zheng Y, et al. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol. 2020;76(7):913\u201322. https:\/\/doi.org\/10.1007\/s00228-020-02860-w.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1867_CR14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jcpt.13250","volume":"45","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Wang J, Liu H, et al. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020;45(6):1434\u201341. https:\/\/doi.org\/10.1111\/jcpt.13250.","journal-title":"J Clin Pharm Ther"},{"key":"1867_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","volume":"17","author":"J Liu","year":"2021","unstructured":"Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325\u201332. https:\/\/doi.org\/10.2147\/TCRM.S302850.","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"1867_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.21037\/tau-22-522","volume":"11","author":"W Xie","year":"2022","unstructured":"Xie W, Ma K, Xu Z, et al. Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study. Transl Androl Urol. 2022;11(10):1410\u20138. https:\/\/doi.org\/10.21037\/tau-22-522.","journal-title":"Transl Androl Urol"},{"issue":"4","key":"1867_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/1120009X.2018.1452333","volume":"30","author":"HA Hakeam","year":"2018","unstructured":"Hakeam HA, Al Duhailib Z, Salahuddin N, et al. Impact of tigecycline versus imipenem-cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study. J Chemother. 2018;30(4):224\u201332. https:\/\/doi.org\/10.1080\/1120009X.2018.1452333.","journal-title":"J Chemother"},{"issue":"4","key":"1867_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s11096-020-01072-7","volume":"42","author":"D Campany-Herrero","year":"2020","unstructured":"Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P, et al. Tigecycline-associated hypofibrinogenemia in a real-world setting. Int J Clin Pharm. 2020;42(4):1184\u20139. https:\/\/doi.org\/10.1007\/s11096-020-01072-7.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"1867_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/1120009X.2022.2105488","volume":"35","author":"H Lei","year":"2023","unstructured":"Lei H, Liu X, Li Z, et al. Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia. J Chemother. 2023;35(4):292\u20137. https:\/\/doi.org\/10.1080\/1120009X.2022.2105488.","journal-title":"J Chemother"},{"issue":"6","key":"1867_CR20","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11096-019-00912-5","volume":"41","author":"N Cui","year":"2019","unstructured":"Cui N, Cai H, Li Z, et al. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019;41(6):1408\u201313. https:\/\/doi.org\/10.1007\/s11096-019-00912-5.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"1867_CR21","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/AAC.04305-14","volume":"59","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015;59(3):1650\u20135. https:\/\/doi.org\/10.1128\/AAC.04305-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1867_CR22","doi-asserted-by":"publisher","first-page":"ofac591","DOI":"10.1093\/ofid\/ofac591","volume":"9","author":"E Rausch","year":"2022","unstructured":"Rausch E, Vemuri K, Anderman TM, et al. Eravacycline associated hypofibrinogenemia: a case series of transplant patients with mycobacterium abscessus infections and review of literature. Open Forum Infect Dis. 2022;9(12):ofac591. https:\/\/doi.org\/10.1093\/ofid\/ofac591.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1867_CR23","doi-asserted-by":"publisher","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","volume":"8","author":"T Morrisette","year":"2021","unstructured":"Morrisette T, Alosaimy S, Philley JV, et al. Preliminary, real-world, multicenter experience with omadacycline for mycobacterium abscessus infections. Open Forum Infect Dis. 2021;8(2):ofab002. https:\/\/doi.org\/10.1093\/ofid\/ofab002.","journal-title":"Open Forum Infect Dis"},{"key":"1867_CR24","doi-asserted-by":"publisher","first-page":"1182644","DOI":"10.3389\/fphar.2023.1182644","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Cai X, Peng F, et al. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone\/sulbactam therapy and other tigecycline-based combination therapies. Front Pharmacol. 2023;14:1182644. https:\/\/doi.org\/10.3389\/fphar.2023.1182644.","journal-title":"Front Pharmacol"},{"key":"1867_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijid.2022.08.014","volume":"123","author":"X Yang","year":"2022","unstructured":"Yang X, Jin L, Luo X, et al. Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: a retrospective cohort study. Int J Infect Dis. 2022;123:136\u201342. https:\/\/doi.org\/10.1016\/j.ijid.2022.08.014.","journal-title":"Int J Infect Dis"},{"issue":"8","key":"1867_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/1120009X.2020.1800318","volume":"32","author":"MX Li","year":"2020","unstructured":"Li MX, Li N, Zhu LQ, et al. Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment. J Chemother. 2020;32(8):420\u20138. https:\/\/doi.org\/10.1080\/1120009X.2020.1800318.","journal-title":"J Chemother"},{"issue":"6","key":"1867_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/FTD.0000000000001115","volume":"45","author":"X Yang","year":"2023","unstructured":"Yang X, Jin L, Luo X, et al. Pharmacokinetic\/pharmacodynamic target attainment of tigecycline in patients with hepatic impairment in a real-world setting. Ther Drug Monit. 2023;45(6):786\u201391. https:\/\/doi.org\/10.1097\/FTD.0000000000001115.","journal-title":"Ther Drug Monit"},{"issue":"43","key":"1867_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022638","volume":"99","author":"Q Fan","year":"2020","unstructured":"Fan Q, Huang W, Weng Y, et al. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Medicine. 2020;99(43):e22638. https:\/\/doi.org\/10.1097\/MD.0000000000022638.","journal-title":"Medicine"},{"issue":"6","key":"1867_CR29","first-page":"915","volume":"19","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhou J. Fibrinogenopenia caused by tigecycline: a case report. Eur Rev Med Pharmacol Sci. 2015;19(6):915\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1867_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.idcr.2018.01.003","volume":"11","author":"PC Wu","year":"2018","unstructured":"Wu PC, Wu CC. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56\u20137. https:\/\/doi.org\/10.1016\/j.idcr.2018.01.003.","journal-title":"IDCases"},{"issue":"3","key":"1867_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1248\/cpb.c18-00844","volume":"67","author":"B Leng","year":"2019","unstructured":"Leng B, Xue YC, Zhang W, et al. A retrospective analysis of the effect of tigecycline on coagulation function. Chem Pharm Bull. 2019;67(3):258\u201364. https:\/\/doi.org\/10.1248\/cpb.c18-00844.","journal-title":"Chem Pharm Bull"},{"issue":"20","key":"1867_CR32","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.3390\/jcm10204702","volume":"10","author":"B Treml","year":"2021","unstructured":"Treml B, Rajsic S, Hell T, et al. Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis. J Clin Med. 2021;10(20):4702. https:\/\/doi.org\/10.3390\/jcm10204702.","journal-title":"J Clin Med"},{"issue":"2","key":"1867_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/antibiotics9020084","volume":"9","author":"A Brandtner","year":"2020","unstructured":"Brandtner A, Bachler M, Fries D, et al. Tigecycline interferes with fibrinogen polymerization independent of peripheral interactions with the coagulation system. Antibiotics. 2020;9(2):84. https:\/\/doi.org\/10.3390\/antibiotics9020084.","journal-title":"Antibiotics"},{"issue":"4","key":"1867_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1039\/c2mb05393d","volume":"8","author":"A Urbani","year":"2012","unstructured":"Urbani A, Lupisella S, Sirolli V, et al. Proteomic analysis of protein adsorption capacity of different haemodialysis membranes. Mol Biosyst. 2012;8(4):1029\u201339. https:\/\/doi.org\/10.1039\/c2mb05393d.","journal-title":"Mol Biosyst"},{"issue":"19","key":"1867_CR35","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1053\/euhj.1999.2207","volume":"21","author":"A Woods","year":"2000","unstructured":"Woods A, Brull DJ, Humphries SE, et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21(19):1574\u201383. https:\/\/doi.org\/10.1053\/euhj.1999.2207.","journal-title":"Eur Heart J"},{"issue":"9","key":"1867_CR36","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1161\/ATVBAHA.114.304114","volume":"34","author":"TJ Gould","year":"2014","unstructured":"Gould TJ, Vu TT, Swystun LL, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014;34(9):1977\u201384. https:\/\/doi.org\/10.1161\/ATVBAHA.114.304114.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1867_CR37","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1161\/ATVBAHA.115.306035","volume":"35","author":"TJ Gould","year":"2015","unstructured":"Gould TJ, Vu TT, Stafford AR, et al. Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis. Arterioscler Thromb Vasc Biol. 2015;35(12):2544\u201353. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306035.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1867_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jac\/dki260","volume":"56","author":"CT Ong","year":"2005","unstructured":"Ong CT, Babalola CP, Nightingale CH, et al. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother. 2005;56(3):498\u2013501. https:\/\/doi.org\/10.1093\/jac\/dki260.","journal-title":"J Antimicrob Chemother"},{"key":"1867_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae180","author":"HI Brunner","year":"2024","unstructured":"Brunner HI, Ruperto N, Ramanan AV, et al. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. Rheumatology. 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae180.","journal-title":"Rheumatology"},{"issue":"11","key":"1867_CR40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/CM9.0000000000000866","volume":"133","author":"JY Zhao","year":"2020","unstructured":"Zhao JY, Yan JY, Qu JM. Interpretations of \u201cDiagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).\u201d Chin Med J. 2020;133(11):1347\u20139. https:\/\/doi.org\/10.1097\/CM9.0000000000000866.","journal-title":"Chin Med J"},{"issue":"9","key":"1867_CR41","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","volume":"13","author":"M Sheppard","year":"2017","unstructured":"Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972\u201388. https:\/\/doi.org\/10.1080\/21645515.2017.1316909.","journal-title":"Hum Vaccin Immunother"},{"key":"1867_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/IDR.S388438","volume":"16","author":"Z Li","year":"2023","unstructured":"Li Z, Zeng Q, Xu S, et al. Development and validation of a nomogram for predicting tigecycline-related coagulopathy: a retrospective cohort study. Infect Drug Resist. 2023;16:423\u201334. https:\/\/doi.org\/10.2147\/IDR.S388438.","journal-title":"Infect Drug Resist"},{"issue":"7","key":"1867_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102568","volume":"19","author":"P Toniati","year":"2020","unstructured":"Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. https:\/\/doi.org\/10.1016\/j.autrev.2020.102568.","journal-title":"Autoimmun Rev"},{"key":"1867_CR44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284564","author":"M Perl","year":"2024","unstructured":"Perl M, Herfeld K, Harrer DC, et al. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Haematologica. 2024;109(9):2969-77. https:\/\/doi.org\/10.3324\/haematol.2023.284564.","journal-title":"Haematologica"},{"issue":"1","key":"1867_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14787210.2020.1800453","volume":"19","author":"K Tomasiewicz","year":"2021","unstructured":"Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. Expert Rev Anti Infect Ther. 2021;19(1):93\u2013100. https:\/\/doi.org\/10.1080\/14787210.2020.1800453.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"1867_CR46","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1080\/14397595.2018.1428041","volume":"28","author":"H Imamura","year":"2018","unstructured":"Imamura H, Momohara S, Yano K, et al. Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol. 2018;28(6):976\u201380. https:\/\/doi.org\/10.1080\/14397595.2018.1428041.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1867_CR47","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jbspin.2016.04.008","volume":"84","author":"N Martis","year":"2017","unstructured":"Martis N, Chirio D, Queyrel-Moranne V, et al. Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. Joint Bone Spine. 2017;84(3):369\u201370. https:\/\/doi.org\/10.1016\/j.jbspin.2016.04.008.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"1867_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","volume":"36","author":"T Okano","year":"2016","unstructured":"Okano T, Inui K, Tada M, et al. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int. 2016;36(3):349\u201357. https:\/\/doi.org\/10.1007\/s00296-015-3379-x.","journal-title":"Rheumatol Int"},{"issue":"4","key":"1867_CR49","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00296-019-04268-x","volume":"39","author":"D Uskudar Cansu","year":"2019","unstructured":"Uskudar Cansu D, Demirtas E, Andic N, et al. Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review. Rheumatol Int. 2019;39(4):743\u201350. https:\/\/doi.org\/10.1007\/s00296-019-04268-x.","journal-title":"Rheumatol Int"},{"issue":"4","key":"1867_CR50","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","volume":"74","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694\u2013702. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204345.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1867_CR51","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10067-024-06937-0","volume":"43","author":"Q An","year":"2024","unstructured":"An Q, Ma R, Yuan D, et al. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia. Clin Rheumatol. 2024;43(5):1491\u2013501. https:\/\/doi.org\/10.1007\/s10067-024-06937-0.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1867_CR52","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14740338.2024.2327503","volume":"23","author":"JJ Li","year":"2024","unstructured":"Li JJ, Chen L, Zhao Y, et al. Data mining and safety analysis of traditional immunosuppressive drugs: a pharmacovigilance investigation based on the FAERS database. Expert Opin Drug Saf. 2024;23(4):513\u201325. https:\/\/doi.org\/10.1080\/14740338.2024.2327503.","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"1867_CR53","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1111\/jth.15074","volume":"18","author":"TF Wang","year":"2020","unstructured":"Wang TF, Makar RS, Antic D, et al. Management of hemostatic complications in acute leukemia: guidance from the SSC of the ISTH. J Thromb Haemost. 2020;18(12):3174\u201383. https:\/\/doi.org\/10.1111\/jth.15074.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1867_CR54","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/ejh.12600","volume":"96","author":"I Aldoss","year":"2016","unstructured":"Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375\u201380. https:\/\/doi.org\/10.1111\/ejh.12600.","journal-title":"Eur J Haematol"},{"issue":"10","key":"1867_CR55","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3324\/haematol.12948","volume":"93","author":"M Hunault-Berger","year":"2008","unstructured":"Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93(10):1488\u201394. https:\/\/doi.org\/10.3324\/haematol.12948.","journal-title":"Haematologica"},{"issue":"3","key":"1867_CR56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood.2020004919","volume":"136","author":"C Orvain","year":"2020","unstructured":"Orvain C, Balsat M, Tavernier E, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020;136(3):328\u201338. https:\/\/doi.org\/10.1182\/blood.2020004919.","journal-title":"Blood"},{"issue":"4","key":"1867_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/ajh.20230","volume":"77","author":"G Beinart","year":"2004","unstructured":"Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77(4):331\u20135. https:\/\/doi.org\/10.1002\/ajh.20230.","journal-title":"Am J Hematol"},{"issue":"1","key":"1867_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0049-3848(90)90193-g","volume":"57","author":"F Rodeghiero","year":"1990","unstructured":"Rodeghiero F, Castaman G, Dini E. Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. Thromb Res. 1990;57(1):31\u20138. https:\/\/doi.org\/10.1016\/0049-3848(90)90193-g.","journal-title":"Thromb Res"},{"issue":"3","key":"1867_CR59","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4143\/crt.2017.051","volume":"50","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Ock CY, Kim TM, et al. Comparison of native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in combination with Ifosfamide, methotrexate, etoposide, and prednisolone, in extranodal NK\/T-cell lymphoma, nasal type. Cancer Res Treat. 2018;50(3):670\u201380. https:\/\/doi.org\/10.4143\/crt.2017.051.","journal-title":"Cancer Res Treat"},{"issue":"7","key":"1867_CR60","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/jcm11071776","volume":"11","author":"E Buzzatti","year":"2022","unstructured":"Buzzatti E, Forghieri F, Paterno G, et al. In BCR-ABL1 positive B-cell acute lymphoblastic leukemia, steroid therapy induces hypofibrinogenemia. J Clin Med. 2022;11(7):1776. https:\/\/doi.org\/10.3390\/jcm11071776.","journal-title":"J Clin Med"},{"issue":"10","key":"1867_CR61","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1080\/10428194.2020.1765236","volume":"61","author":"C Gaulin","year":"2020","unstructured":"Gaulin C, Chan A, Derkach A, et al. Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(10):2497\u2013501. https:\/\/doi.org\/10.1080\/10428194.2020.1765236.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"1867_CR62","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1080\/10428194.2018.1429603","volume":"59","author":"M Sciume","year":"2018","unstructured":"Sciume M, Fracchiolla NS, Cortelezzi A. Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(10):2516\u20137. https:\/\/doi.org\/10.1080\/10428194.2018.1429603.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"1867_CR63","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1161\/STROKEAHA.115.011290","volume":"46","author":"X Huang","year":"2015","unstructured":"Huang X, Moreton FC, Kalladka D, et al. Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke. Stroke. 2015;46(12):3543\u20136. https:\/\/doi.org\/10.1161\/STROKEAHA.115.011290.","journal-title":"Stroke"},{"issue":"13","key":"1867_CR64","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1212\/WNL.0b013e3182897015","volume":"80","author":"B Matosevic","year":"2013","unstructured":"Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology. 2013;80(13):1216\u201324. https:\/\/doi.org\/10.1212\/WNL.0b013e3182897015.","journal-title":"Neurology"},{"issue":"2","key":"1867_CR65","doi-asserted-by":"publisher","first-page":"219","DOI":"10.17219\/acem\/84936","volume":"28","author":"L Vandelli","year":"2019","unstructured":"Vandelli L, Marietta M, Trenti T, et al. Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment. Adv Clin Exp Med. 2019;28(2):219\u201322. https:\/\/doi.org\/10.17219\/acem\/84936.","journal-title":"Adv Clin Exp Med"},{"issue":"10","key":"1867_CR66","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1161\/STROKEAHA.119.025711","volume":"50","author":"S Yan","year":"2019","unstructured":"Yan S, Zhang X, Zhang R, et al. Early fibrinogen depletion and symptomatic intracranial hemorrhage after reperfusion therapy. Stroke. 2019;50(10):2716\u201321. https:\/\/doi.org\/10.1161\/STROKEAHA.119.025711.","journal-title":"Stroke"},{"issue":"9","key":"1867_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024978","volume":"100","author":"X Huang","year":"2021","unstructured":"Huang X, Cao L. Rare severe hypofibrinogenemia induced by tissue plasminogen activator in stroke patients: case report. Medicine. 2021;100(9):e24978. https:\/\/doi.org\/10.1097\/MD.0000000000024978.","journal-title":"Medicine"},{"issue":"7","key":"1867_CR68","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1538574413497107","volume":"47","author":"N Skeik","year":"2013","unstructured":"Skeik N, Gits CC, Ehrenwald E, et al. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis. Vasc Endovasc Surg. 2013;47(7):519\u201323. https:\/\/doi.org\/10.1177\/1538574413497107.","journal-title":"Vasc Endovasc Surg"},{"key":"1867_CR69","doi-asserted-by":"publisher","unstructured":"Cai L, Wen X, Qiu Z, et al. Characteristics, risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia: a retrospective real-world study of inpatients. BMC Pharmacol Toxicol. 2025;26(1):5. https:\/\/doi.org\/10.1186\/s40360-024-00827-6.","DOI":"10.1186\/s40360-024-00827-6"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01867-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T02:36:23Z","timestamp":1748572583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01867-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01867-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5326354\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicting interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}